Retina Treatment | WHO News

March 30, 2023

Advancement in Geographic Atrophy Treatment

For more than 100 years, Wolfe Eye Clinic has been Iowa’s leader in the treatment of and research into a wide variety of eye diseases. We continue to strive every day to meet the needs of our patients, and we are thrilled to be able to offer a new retinal disease treatment that will greatly benefit patients diagnosed with Geographic Atrophy. We are excited to offer this treatment to patients and potentially slow the progression of the retinal disease.

On February 23rd , the U.S. Food and Drug Administration (FDA) approved the use of Syfovre™, a new retina drug able treat an advanced form of age-related macular degeneration (AMD), Geographic Atrophy (GA). This drug is similar to other retinal treatments and the medication is administered via a painless injection into the eye. Geographic Atrophy affects more than 1 million people in the U.S. and nearly 20,000 Iowans. It is a leading cause of blindness in adults over 60 and this groundbreaking milestone will provide – for the first time ever – a treatment for those with GA. With a high population of Iowans who suffer from or who are at risk of developing AMD, this is a breakthrough for treatment that Wolfe Eye Clinic is pleased to offer in addition to the many specialty medical eye care services and surgeries for Iowans. We are sharing this great news with our patients, referral partners and others.


Wolfe Eye Clinic in the news!

We are excited to share that WHO News Channel 13 aired a segment on the Wolfe Retina department this morning! The segment specifically covered the new approved medication through an interview with our very own Jared Nielsen, MD. While not directly involved in the clinical trials of Syfovre, Wolfe Eye Clinic is proud to offer this treatment to patients and potentially slow the progression of GA. This retinal disease, it is a degenerative condition of the macula and leads to permanent visual loss. This disease can be devastating and debilitating to patients affected. Although Syfovre will not cure the disease, we are fortunate to finally be able to offer patients a treatment and potential hope. Check out Dr. Jared Nielsen's interview with WHO Channel 13 below!

We are committed to helping our patients live their best lives through top-of-the-line eye care. That’s why our retina specialists consistently lead studies and treatments of eye diseases such as AMD and GA. This pioneering research adds to the ongoing advances in specialized services and we could not be more thrilled to bring this new advancement to our local Iowan's.